Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Laboratorios Farmaceuticos Rovi, SA (GB:0ILL)
LSE:0ILL
RESEARCH TOOLSreports
Holding GB:0ILL?
Track your performance easily
0ILL Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€46.72 - €93.90
Previous Close€75.25
Volume4.58K
Average Volume (3M)7.20K
Market Cap
€3.81B
Enterprise Value€3.75B
Total Cash (Recent Filing)€124.94M
Total Debt (Recent Filing)€72.14M
Price to Earnings (P/E)22.9
Beta0.18
Next Earnings
Nov 07, 2024EPS EstimateN/A
Last Dividend Ex-Date
Jul 08, 2024Dividend Yield1.2%
Share Statistics
EPS (TTM)3.22
Shares OutstandingN/A
10 Day Avg. Volume10,482
30 Day Avg. Volume7,196
Standard Deviation0.10
R-Squared0.06
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)0.02
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€99.00Price Target Upside31.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Laboratorios Farmaceuticos Rovi News
PremiumCompany Announcements
ROVI Completes Share Capital Reduction and Adjusts Ownership
PremiumCompany Announcements
ROVI Announces Capital Reduction and Share Redemption
PremiumCompany Announcements
ROVI Modifies Liquidity Contract Balances
PremiumCompany Announcements
ROVI Sets Dividend Payout for July 10, 2024
PremiumCompany Announcements
ROVI Reports Dynamic Trading in Q2 2024
PremiumCompany Announcements
ROVI Receives Offers for Manufacturing BusinessPremiumCompany Announcements
ROVI Shareholders Approve Dividends and ElectionsOptions Prices
Currently, No data available
---
Ownership Overview
63.66%
Insiders
6.24% Mutual Funds
1.96% Other Institutional Investors
28.14% Public Companies and
Individual Investors
0ILL FAQ
What was Laboratorios Farmaceuticos Rovi, SA’s price range in the past 12 months?
Laboratorios Farmaceuticos Rovi, SA lowest share price was €46.72 and its highest was €93.90 in the past 12 months.
What is Laboratorios Farmaceuticos Rovi, SA’s market cap?
Currently, no data Available
When is Laboratorios Farmaceuticos Rovi, SA’s upcoming earnings report date?
Laboratorios Farmaceuticos Rovi, SA’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Laboratorios Farmaceuticos Rovi, SA’s earnings last quarter?
Laboratorios Farmaceuticos Rovi, SA released its earnings results on Jul 31, 2024. The company reported €0.86 earnings per share for the quarter, beating the consensus estimate of N/A by €0.86.
Is Laboratorios Farmaceuticos Rovi, SA overvalued?
According to Wall Street analysts Laboratorios Farmaceuticos Rovi, SA’s price is currently Undervalued.
Does Laboratorios Farmaceuticos Rovi, SA pay dividends?
Laboratorios Farmaceuticos Rovi, SA pays a Annually dividend of €0.89 which represents an annual dividend yield of 1.2%. See more information on Laboratorios Farmaceuticos Rovi, SA dividends here
What is Laboratorios Farmaceuticos Rovi, SA’s EPS estimate?
Laboratorios Farmaceuticos Rovi, SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Laboratorios Farmaceuticos Rovi, SA have?
Laboratorios Farmaceuticos Rovi, SA has 51,235,764 shares outstanding.
What happened to Laboratorios Farmaceuticos Rovi, SA’s price movement after its last earnings report?
Laboratorios Farmaceuticos Rovi, SA reported an EPS of €0.86 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.103%.
Which hedge fund is a major shareholder of Laboratorios Farmaceuticos Rovi, SA?
Currently, no hedge funds are holding shares in GB:0ILL
---
Laboratorios Farmaceuticos Rovi Stock Smart Score
Company Description
Laboratorios Farmaceuticos Rovi, SA
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments.
---
0ILL Stock 12 Month Forecast
Average Price Target
€99.00
▲(31.56% Upside)
Technical Analysis
Best Analysts Covering 0ILL
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
+4.80%
reiterated a buy rating 11 days ago
Copying Pablo de Renteria's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of +4.80% per trade.
---